Cytrx cancer drug shows promise in trial, shares rise

(Reuters) – Cytrx Corp said interim data showed its experimental cancer drug was effective in a mid-stage trial on patients with a deadly form of brain cancer, sending its shares up 33 percent before the bell. The drug, aldoxorubicin, was tested in patients with glioblastoma multiforme (GBM) whose tumors had progressed post surgery as well as radiation and was successful in preventing further progression and shrank tumors in several patients. GBM is the most deadly form of brain cancer and affects more than 12,000 people in the United States annually, the company said. …
Go to Source